Ensign Peak Advisors’s Pacira BioSciences PCRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $110K | Hold |
4,870
| – | – | ﹤0.01% | 1541 |
|
|
2025
Q4 | $126K | Sell |
4,870
-13,450
| -73% | -$320K | ﹤0.01% | 1509 |
|
|
2025
Q3 | $472K | Sell |
18,320
-2,700
| -13% | -$66.3K | ﹤0.01% | 1408 |
|
|
2025
Q2 | $502K | Hold |
21,020
| – | – | ﹤0.01% | 1553 |
|
|
2025
Q1 | $522K | Hold |
21,020
| – | – | ﹤0.01% | 1537 |
|
|
2024
Q4 | $396K | Hold |
21,020
| – | – | ﹤0.01% | 1651 |
|
|
2024
Q3 | $316K | Hold |
21,020
| – | – | ﹤0.01% | 1669 |
|
|
2024
Q2 | $601K | Hold |
21,020
| – | – | ﹤0.01% | 1552 |
|
|
2024
Q1 | $614K | Sell |
21,020
-1,060
| -5% | -$32.6K | ﹤0.01% | 1575 |
|
|
2023
Q4 | $745K | Hold |
22,080
| – | – | ﹤0.01% | 1537 |
|
|
2023
Q3 | $677K | Hold |
22,080
| – | – | ﹤0.01% | 1460 |
|
|
2023
Q2 | $885K | Hold |
22,080
| – | – | ﹤0.01% | 1361 |
|
|
2023
Q1 | $901K | Hold |
22,080
| – | – | ﹤0.01% | 1328 |
|
|
2022
Q4 | $853K | Buy |
22,080
+5,400
| +32% | +$263K | ﹤0.01% | 1290 |
|
|
2022
Q3 | $887K | Sell |
16,680
-1,750
| -9% | -$97.3K | ﹤0.01% | 1136 |
|
|
2022
Q2 | $1.07M | Hold |
18,430
| – | – | ﹤0.01% | 1081 |
|
|
2022
Q1 | $1.41M | Hold |
18,430
| – | – | ﹤0.01% | 1033 |
|
|
2021
Q4 | $1.11M | Sell |
18,430
-9,170
| -33% | -$506K | ﹤0.01% | 1222 |
|
|
2021
Q3 | $1.55M | Hold |
27,600
| – | – | ﹤0.01% | 1250 |
|
|
2021
Q2 | $1.68M | Hold |
27,600
| – | – | ﹤0.01% | 1221 |
|
|
2021
Q1 | $1.93M | Buy |
27,600
+2,300
| +9% | +$164K | ﹤0.01% | 1130 |
|
|
2020
Q4 | $1.51M | Buy |
25,300
+5,500
| +28% | +$322K | ﹤0.01% | 1212 |
|
|
2020
Q3 | $1.19M | Hold |
19,800
| – | – | ﹤0.01% | 1235 |
|
|
2020
Q2 | $1.04M | Hold |
19,800
| – | – | ﹤0.01% | 1266 |
|
|
2020
Q1 | $664K | Buy |
19,800
+10,500
| +113% | +$436K | ﹤0.01% | 1309 |
|
|
2019
Q4 | $421K | Buy |
+9,300
| New | +$395K | ﹤0.01% | 1538 |
|
Other funds holding PCRX
DPCM
VPM
VCM
